Vertex Pharmaceuticals/$VRTX
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Vertex Pharmaceuticals
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Ticker
$VRTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
6,100
ISIN
US92532F1003
Website
VRTX Metrics
BasicAdvanced
$115B
-
-$3.84
0.51
-
Price and volume
Market cap
$115B
Beta
0.51
52-week high
$519.68
52-week low
$377.85
Average daily volume
1.6M
Financial strength
Current ratio
2.646
Quick ratio
2.116
Long term debt to equity
9.997
Total debt to equity
9.997
Interest coverage (TTM)
189.98%
Profitability
EBITDA (TTM)
4,584.4
Gross margin (TTM)
53.09%
Net profit margin (TTM)
-8.91%
Operating margin (TTM)
39.71%
Effective tax rate (TTM)
-229.41%
Revenue per employee (TTM)
$1,820,000
Management effectiveness
Return on assets (TTM)
11.77%
Return on equity (TTM)
-5.64%
Valuation
Price to revenue (TTM)
10.405
Price to book
6.99
Price to tangible book (TTM)
7.7
Price to free cash flow (TTM)
-91.81
Free cash flow yield (TTM)
-1.09%
Free cash flow per share (TTM)
-488.40%
Growth
Revenue change (TTM)
8.98%
Earnings per share change (TTM)
-124.93%
3-year revenue growth (CAGR)
11.78%
10-year revenue growth (CAGR)
33.87%
3-year earnings per share growth (CAGR)
-25.99%
10-year earnings per share growth (CAGR)
2.58%
What the Analysts think about VRTX
Analyst ratings (Buy, Hold, Sell) for Vertex Pharmaceuticals stock.
Bulls say / Bears say
Vertex Pharmaceuticals received a positive opinion from the European Medicines Agency's CHMP for expanding the label of KAFTRIO® in combination with ivacaftor, potentially making approximately 4,000 additional patients in the European Union eligible for treatment. (stocktitan.net)
The company reported strong financial results for Q4 and full year 2024, with full-year product revenue reaching $11.02 billion, a 12% increase from 2023, and provided 2025 revenue guidance of $11.75 to $12.0 billion. (stocktitan.net)
Vertex's acute pain drug, Journavx, launched in March 2025, has generated more than 20,000 prescriptions through April 18, indicating a promising start for this new product. (reuters.com)
Vertex Pharmaceuticals missed Wall Street estimates for Q1 2025 due to lower-than-expected sales of its cystic fibrosis drug Trikafta, with sales rising only 2% to $2.53 billion, below analysts' expectations of $2.58 billion. (reuters.com)
The company's nonaddictive drug for lower back pain did not outperform a placebo in a midstage trial, causing shares to fall as much as 16% and raising questions about the drug's potential as a significant growth driver. (bloomberg.com)
Analysts have lowered their price targets for Vertex Pharmaceuticals, with Barclays reducing its target from $509.00 to $418.00 and setting an 'equal weight' rating, reflecting concerns about the company's growth prospects. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 22 May 2025.
VRTX Financial Performance
Revenues and expenses
VRTX Earnings Performance
Company profitability
VRTX News
AllArticlesVideos
3 Monster Stocks to Confidently Own for the Next 10 Years
24/7 Wall Street·5 days ago
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference
Business Wire·2 weeks ago
Vertex to Participate in Upcoming Investor Conferences
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Vertex Pharmaceuticals stock?
Vertex Pharmaceuticals (VRTX) has a market cap of $115B as of June 20, 2025.
What is the P/E ratio for Vertex Pharmaceuticals stock?
The price to earnings (P/E) ratio for Vertex Pharmaceuticals (VRTX) stock is 0 as of June 20, 2025.
Does Vertex Pharmaceuticals stock pay dividends?
No, Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Vertex Pharmaceuticals dividend payment date?
Vertex Pharmaceuticals (VRTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Vertex Pharmaceuticals?
Vertex Pharmaceuticals (VRTX) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.